Eisai's Fycompa approved in US with boxed warning, awaits DEA scheduling
This article was originally published in Scrip
Executive Summary
Eisai's novel antiepileptic drug Fycompa (perampanel) has been approved by the US FDA after a bumpy regulatory ride, for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in epilepsy patients aged 12 or older.